- Charlotte’s Web will provide CBD products to older adult oncology patients through a Medicare pilot program starting in 2026.
- The program aims to reduce costs and increase access for low-income individuals via Medicare reimbursement.
CBD company Charlotte’s Web has announced it is partnering with the new pilot program developed by the Center for Medicare and Medicaid Innovation (CMMI) to support older adult oncology patients (1). The company will act as a provider with the program, and starting in early 2026 will offer multiple products for patients through an online healthcare portal.
Program Details
The press release explains that through Medicare reimbursement, the program aims to reduce out of pocket costs for patients and enable low-income individuals to access CBD products.
“Charlotte’s Web is proud to participate in the CMMI program to bring trusted CBD options to underserved seniors battling cancer,” stated CEO Bill Morachnick, in the December 18 press release. “Charlotte’s Web was founded to help Charlotte Figi, whose medically challenging life became a CBD success story. Her journey inspired research, opened doors to access, and changed perceptions about the therapeutic benefits of CBD around the globe. The Company made a promise to Charlotte, her mother Paige, and the millions who followed her: to set the standard for the entire industry by leading with quality, consistency, and science. As the CBD market leader and a trusted partner throughout the country among healthcare practitioners, this initiative marks a historic step forward, uniquely positioning Charlotte’s Web to expand access to safe, non-intoxicating hemp CBD products through existing pathways. We thank the administration, CMMI, and all key stakeholders for their vision and persistence in making this possible.”
Additionally, the company’s Scientific Advisory Board (SAB) will provide advisory guidance. “Scientific rigor underpins every aspect of this program,” explained said Marcel Bonn-Miller, PhD, Chief Scientific Officer at Charlotte’s Web. “With more than a decade of consumer use and extensive safety studies, Charlotte’s Web integrates real-world evidence, patient-reported outcomes, and clinical insights into its R&D process to ensure products are safe and effective.”
Read more at
